UniProt P16410
Cytotoxic T-lymphocyte protein 4 (P16410)
Cytotoxic T-lymphocyte protein 4 (UniProt P16410): 36 experimental structures and 1 predicted model on GenesisL1, 4 ligands bound, 51 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.
- UniProt
- P16410
- Protein
- Cytotoxic T-lymphocyte protein 4
- Experimental structures
- 36
- Predicted models
- 1
- Ligands
- 4
- Pockets
- 51 · 6 records with a druggable one
Structures
37 records of P16410 in the MolNFT archive: 36 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1AH1 | Ctla-4, NMR, 20 structures | solution nmr | A | — | — |
| 1AH1 | Ctla-4, NMR, 20 structures | solution nmr | A | — | — |
| 1H6E | MU2 adaptin subunit (AP50) of AP2 adaptor (second domain), complexed with ctla-4 internalization… | x-ray diffraction | P | — | — |
| 1H6E | MU2 adaptin subunit (AP50) of AP2 adaptor (second domain), complexed with ctla-4 internalization… | x-ray diffraction | P | — | — |
| 1I85 | Crystal structure of the ctla-4/B7-2 complex | x-ray diffraction | C, D | — | — |
| 1I85 | Crystal structure of the ctla-4/B7-2 complex | x-ray diffraction | C, D | — | — |
| 1I8L | Human B7-1/CTLA-4 co-stimulatory complex | x-ray diffraction | C, D | — | — |
| 1I8L | Human B7-1/CTLA-4 co-stimulatory complex | x-ray diffraction | C, D | — | — |
| 2X44 | Structure of a strand-swapped dimeric form of CTLA-4 | x-ray diffraction | D | — | — |
| 2X44 | Structure of a strand-swapped dimeric form of ctla-4 | x-ray diffraction | D | — | — |
| 3BX7 | Engineered Human Lipocalin 2 (LCN2) in Complex with the Extracellular Domain of Human CTLA-4 | x-ray diffraction | C | — | — |
| 3BX7 | Engineered human lipocalin 2 (LCN2) in complex with the extracellular domain of human ctla-4 | x-ray diffraction | C | — | — |
| 3OSK | Crystal structure of human CTLA-4 apo homodimer | x-ray diffraction | A, B | — | — |
| 3OSK | Crystal structure of human ctla-4 apo homodimer | x-ray diffraction | A, B | — | — |
| 5GGV | CTLA-4 in complex with tremelimumab Fab | x-ray diffraction | Y | — | — |
| 5GGV | Ctla-4 in complex with tremelimumab Fab | x-ray diffraction | Y | — | — |
| 5TRU | Structure of the first-in-class checkpoint inhibitor Ipilimumab bound to human CTLA-4 | x-ray diffraction | c, C | — | 6 (best 0.53) |
| 5TRU | Structure of the first-in-class checkpoint inhibitor ipilimumab bound to human ctla-4 | x-ray diffraction | c, C | — | — |
| 5XJ3 | Complex structure of ipilimumab-scFv and CTLA-4 | x-ray diffraction | C, F, I, L | — | 13 (best 0.70) |
| 5XJ3 | Complex structure of ipilimumab-scfv and ctla-4 | x-ray diffraction | C, F, I, L | — | — |
| 6RP8 | Crystal Structure of Ipilimumab Fab complexed with CTLA-4 at 2.6A resolution | x-ray diffraction | C, c | — | — |
| 6RP8 | Crystal structure of ipilimumab Fab complexed with ctla-4 at 2.6A resolution | x-ray diffraction | C, c | — | — |
| 6RPJ | A non-blocking anti-ctla-4 nanobody complexed with ctla-4 | x-ray diffraction | A, C, E, G | NAG, FUC, NA | — |
| 6RQM | A blocking anti-CTLA-4 Nanobody (KN044) complexed with CTLA-4 | x-ray diffraction | A | — | 1 (best 0.31) |
| 6RQM | A blocking anti-ctla-4 nanobody (KN044) complexed with ctla-4 | x-ray diffraction | A | — | — |
| 6XY2 | Crystal structure of ctla-4 complexed with the Fab of HL32 antibody | x-ray diffraction | A | NAG | — |
| 7CIO | Molecular interactions of cytoplasmic region of ctla-4 with SH2 domains of PI3-kinase | x-ray diffraction | B | — | — |
| 7DV4 | Crystal structure of anti-CTLA-4 VH domain in complex with human CTLA-4 | x-ray diffraction | A, C, E, G | — | 7 (best 0.81) |
| 7DV4 | Crystal structure of anti-ctla-4 vh domain in complex with human ctla- 4 | x-ray diffraction | A, C, E, G | — | — |
| 7ELX | The crystal structure of CTLA-4 and Fab | x-ray diffraction | c, C | — | 11 (best 0.77) |
| 7ELX | The crystal structure of ctla-4 and Fab | x-ray diffraction | c, C | — | — |
| 7SU0 | Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.105 in complex with CTLA-4 | x-ray diffraction | C, D | NAG | 9 (best 0.76) |
| 7SU0 | Crystal structure of an acidic pH-selective ipilimumab variant IPI.105 in complex with ctla-4 | x-ray diffraction | C, D | NAG | — |
| 7SU1 | Crystal structure of an acidic pH-selective ipilimumab variant IPI.106 in complex with ctla-4 | x-ray diffraction | C | NAG | — |
| 8GAB | Crystal structure of CTLA-4 in complex with a high affinity CTLA-4 binder | x-ray diffraction | B, D | K | 3 (best 0.69) |
| 8HIT | Crystal structure of anti-CTLA-4 humanized IgG1 MAb--JS007 in complex with human CTLA-4 | x-ray diffraction | C | — | 1 (best 0.29) |
| P16410 | AlphaFold monomer V2.0 prediction for cytotoxic T-lymphocyte protein 4 (P16410) | predicted | A | — | — |
Ligands
Experiment against prediction
- 1I8L chain C against the predicted model P16410: TM-score 0.97, RMSD 0.73 Å
- 1I8L chain C against the predicted model P16410: TM-score 0.97, RMSD 0.73 Å
- 1I8L chain D against the predicted model P16410: TM-score 0.97, RMSD 0.76 Å
- 1I8L chain D against the predicted model P16410: TM-score 0.97, RMSD 0.76 Å
- 7SU0 chain D against the predicted model P16410: TM-score 0.97, RMSD 0.91 Å
- 7SU0 chain D against the predicted model P16410: TM-score 0.97, RMSD 0.91 Å
- 7SU0 chain C against the predicted model P16410: TM-score 0.97, RMSD 0.92 Å
- 7SU0 chain C against the predicted model P16410: TM-score 0.97, RMSD 0.92 Å
- 5TRU chain c against the predicted model P16410: TM-score 0.96, RMSD 0.90 Å
- 5TRU chain c against the predicted model P16410: TM-score 0.96, RMSD 0.90 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.